



Year: 2014

A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients

Szkandera, J ; Pichler, M ; Absenger, G ; Stotz, M ; Weissmueller, M ; Samonigg, H ; Asslaber, M ;
Lax, S ; Leitner, G ; Winder, T ; Renner, W ; Gerger, A

Abstract: **PURPOSE:** Cumulating evidence indicates that germline variants in the Wnt, Notch, and Hedgehog pathways are involved in colon carcinoma progression and metastasis. We investigated germline polymorphisms in a comprehensive panel of Wnt, Notch, and Hedgehog pathway genes to predict time to recurrence (TTR) and overall survival in patients with stage II and III colon carcinoma. **EXPERIMENTAL DESIGN:** A total of 742 consecutively collected patients with stage II and III colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 18 germline polymorphisms in Wnt, Notch, and Hedgehog pathway genes (SFRP, DKK 2 and 3, AXIN2, APC, MYC, TCF7L2, NOTCH2, and GLI1) by TaqMan 5'-exonuclease assays. **RESULTS:** In univariate analysis, the homozygous mutant variant of GLI1 rs2228226 G>C was significantly associated with decreased TTR in a recessive genetic model after adjustment for multiple testing [HR = 2.35; confidence interval (95% CI), 1.48-3.74; P < 0.001] and remained significant in multivariate analysis including clinical stage, lymphovascular-, vascular-, and perineural-invasion (HR = 2.43; CI 95%, 1.52-3.87; P < 0.001). In subanalyses, the association was limited to patients with surgery alone (HR = 3.21; CI 95%, 1.59-6.49; P = 0.001), in contrast with patients with adjuvant chemotherapy (HR = 0.82; CI 95%, 0.35-1.95; P = 0.657). When the subgroup of patients with "high-risk" GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-fluorouracil-based chemotherapy could be found. **CONCLUSION:** This is the first study identifying GLI1 rs2228226 G>C as an independent prognostic marker in patients with stage II and III colon carcinoma. Prospective studies are warranted to validate our findings.

DOI: <https://doi.org/10.1158/1078-0432.CCR-13-1517>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-106843>

Journal Article

Accepted Version

Originally published at:

Szkandera, J; Pichler, M; Absenger, G; Stotz, M; Weissmueller, M; Samonigg, H; Asslaber, M; Lax, S; Leitner, G; Winder, T; Renner, W; Gerger, A (2014). A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. *Clinical Cancer Research*, 20(6):1687-1697.

DOI: <https://doi.org/10.1158/1078-0432.CCR-13-1517>

A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients

Running title: GLI1 variant and colon carcinoma

Joanna Szkandera^{1,2}, Martin Pichler¹, Gudrun Absenger^{1,2}, Michael Stotz¹, Melanie Weissmueller¹, Hellmut Samonigg¹, Martin Asslaber³, Sigurd Lax⁴, Gerhard Leitner⁵, Thomas Winder⁶, Wilfried Renner⁷ and Armin Gerger^{1,2*}

¹Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria

²Research Unit: Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Medical University of Graz, Graz, Austria

³Institute of Pathology, Medical University of Graz, Graz, Austria

⁴Department of Pathology, General Hospital Graz West, Graz, Austria

⁵Department of Pathology, General Hospital of Leoben, Leoben, Austria

⁶Department of Medical Oncology, University Hospital Zuerich, Zuerich, Switzerland

⁷Clinical Institute of Medical and Laboratory Diagnostics, Medical University of Graz, Graz, Austria

*Corresponding author: Armin Gerger, MD, Assoc.-Prof., Priv.-Doz., Division of Clinical Oncology, Research Unit: Genetic Epidemiology and Pharmacogenetics, Department of Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria; Phone: +43-316-385-80625, Fax: +43-316-385-13355, e-mail: armin.gerger@medunigraz.at.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This study was supported by funds of the Oesterreichische Nationalbank (Anniversary Fund, project number: 14258)

Key words

Germline polymorphism, Hedgehog pathway, colon carcinoma

Translational relevance

Germline variants in cancer stem cells (CSCs) may have an important role in tumor recurrence despite adjuvant chemotherapy. In the present study, we investigated germline polymorphisms in a comprehensive panel of genes in the Wnt, Notch and Hedgehog pathways that have been previously investigated for their biological function and/ or associated with CSCs and cancer risk or clinical outcome to predict tumor recurrence in patients with stage II and III colon carcinoma. These common DNA-sequence variations may alter the gene function and/ or activity including transcription, translation or splicing, thereby causing inter-individual differences in relation to tumor recurrence capacity. Our study provides the first evidence that GLI1 rs2228226 G>C may predict early tumor recurrence in stage II and III colon carcinoma patients.

Abstract

Purpose: Cumulating evidence indicates that germline variants in Wnt, Notch and Hedgehog pathways are involved in colon carcinoma progression and metastasis. We investigated germline polymorphisms in a comprehensive panel of Wnt, Notch and Hedgehog pathway genes to predict time to recurrence (TTR) and overall survival (OS) in patients with stage II and III colon carcinoma.

Experimental design: A total of 742 consecutively collected patients with stage II and III colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 18 germline polymorphisms in Wnt, Notch and Hedgehog pathway genes (SFRP, DKK 2 and 3, AXIN2, APC, MYC, TCF7L2, NOTCH2 and GLI1) by TaqMan 5'-exonuclease assays.

Results: In univariate analysis, the homozygous mutant variant of GLI1 rs2228226 G>C was significantly associated with decreased TTR in a recessive genetic model after adjustment for multiple testing (HR 2.35, CI95% 1.48-3.74, $p < 0.001$) and remained significant in multivariate analysis including clinical stage, lymphovascular-, vascular- and perineural-invasion (HR 2.43, CI95% 1.52-3.87, $p < 0.001$). In subanalyses, the association was limited to patients with surgery alone (HR 3.21, CI95% 1.59-6.49, $p = 0.001$), in contrast to patients with adjuvant chemotherapy (HR 0.82, CI95% 0.35-1.95, $p = 0.657$). When the subgroup of patients with “high-risk” GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-FU-based chemotherapy could be found.

Conclusion: This is the first study identifying GLI1 rs2228226 G>C as an independent prognostic marker in stage II and III colon carcinoma patients. Prospective studies are warranted to validate our findings.

Introduction

Colorectal carcinoma is the third cause of cancer-related death in the United States and the second cause of cancer mortality in Europe (1, 2). Across all stages, approximately 30% of patients with colon carcinoma develop synchronous or metachronous metastases (3). The 5-year survival rate of colon carcinoma patients with metastatic disease is less than 10% (4).

In the absence of adjuvant chemotherapy, approximately 50% of colon carcinoma patients with resectable disease are cured by surgery alone, whereas 50% relapse. Using adjuvant chemotherapy following surgery rescues approximately 15% of patients from the relapsing group. In current practice, the majority of these colon carcinoma patients receive adjuvant treatment unnecessarily, either because they were cured by surgery alone or because they will relapse despite adjuvant treatment. It is therefore essential to identify patients who will benefit from adjuvant therapy, sparing others needless toxicity and the financial burden of chemotherapy that will not work (5-7). Tumor recurrence after curative surgery remains a major obstacle for improving overall cancer survival, which may be in part due to the existence of cancer stem cells (CSC). Current therapies target populations of rapidly growing and differentiated tumor cells, but have shown to lack activity against CSCs (8, 9). CSCs therefore may have an important role in tumor recurrence despite adjuvant chemotherapy (9, 10). There is strong evidence that the embryonic signaling pathways Wnt, Notch and Hedgehog operate in CSCs and drive tumor progression, metastasis and chemoresistance (11-18).

There is substantial germline genetic variability within the genes of the Wnt, Notch and Hedgehog pathways, including multiple single nucleotide polymorphisms (SNPs). These

common DNA-sequence variations may alter the gene function and/ or activity including transcription, translation or splicing, thereby causing inter-individual differences in relation to tumor recurrence capacity and chemoresistance (19-29). Furthermore, common gene variants may also predict chemoresistance and toxicity to 5-FU and/ or oxaliplatin as recently shown for the thymidylate synthetase (Ts), 5 methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), multidrug resistance protein 2 (MRP2), dihydropyrimidine dehydrogenase (DPD) and the X-ray repair cross-complementing protein 1 (XRCC1) genes (30-35).

In the present study, we investigated 18 germline polymorphisms in a comprehensive panel of genes in the Wnt, Notch and Hedgehog pathways that have been previously investigated for their biological function and/ or associated with cancer risk or clinical outcome to predict tumor recurrence in patients with stage II and III colon carcinoma. This study was conducted adhering to the reporting recommendations for prognostic tumor marker studies (36, 37).

Materials and methods

Eligible patients

Between 1995 and 2011, 742 patients with histopathologically confirmed stage II and III colon carcinoma were consecutively recruited at the Division of Clinical Oncology, Department of Medicine, Medical University of Graz. Tissue samples from 522 patients were available for current genetic analyses. Tissue samples were provided by the Biobank of the Medical University of Graz, the Department of Pathology of the General Hospital Graz West and the Department of Pathology of the General Hospital Leoben. Patients treated with adjuvant chemotherapy received 5-FU-based regimens. All patients were included in the colon carcinoma surveillance program of the Division of Clinical Oncology of the Medical University of Graz, providing history and physical examination and CEA determination every 3 months for 3 years and every 6 months at years 4 and 5 after surgery, colonoscopy at year 1 and thereafter every 3-5 years and chest X-ray and abdominal ultrasound or CT scans of chest and abdomen every 6 months for the first 5 years and in 12 months interval in years 6-10 after diagnosis. Patient data were collected retrospectively through chart review. This study has been approved by the Institutional Review Board (IRB) of the Medical University of Graz. All participants were Caucasians.

Candidate gene polymorphisms

Common and putatively functional Wnt, Notch and Hedgehog gene polymorphisms were selected using stringent and pre-defined selection criteria: (a) minor allele frequency $\geq 10\%$ in Caucasians (based on the population genetics section in the Ensembl Genome Browser); (b) polymorphism that could alter the function of the gene in a biologically relevant manner (either published data or predicted function using Functional-Single-Nucleotide-

Polymorphism (F-SNP) database (38, 39); (c) published clinical associations (e.g. cancer risk and/ or clinical outcome or chemoresistance). As it was not possible to select all Wnt, Notch and Hedgehog pathway gene variants matching these criteria for study power reasons, we focused on the most promising genes and polymorphisms. Table 1 summarizes the genes and polymorphisms investigated in our study cohort including location and function/ clinical association.

Isolation of genomic DNA and determination of single nucleotide polymorphisms

Genomic DNA was extracted from paraffin-embedded normal tissue adjacent to the tumor samples to obtain germline DNA. DNA isolation was performed by use of the QIAamp DNA mini Kit (Qiagen) and according to the manufacturer's instructions. Genotypes were centrally determined by 5'-exonuclease assay (TaqMan) at the Medical University of Graz. Primer and probe sets were designed and manufactured using Applied Biosystems 'Assay-by-Design' custom service (Applied Biosystems, Austria). General TaqMan reaction conditions were according to the manufacturer of the assays. As a control for consistency of genotyping methods, determination of genotypes was repeated in at least 96 samples. The rules of good laboratory and clinical practice were observed. The investigator analyzing the germline polymorphisms was blinded to the clinical dataset.

Immunohistochemistry

Immunohistochemistry was performed on a Ventana XT immunostainer using UltraView DAB as the detection kit and CC1 32min as heat induced epitope retrieval (HIER). The primary antibody was incubated for 32 minutes each: Anti-Interleukin (IL) 17 antibody ab9565/Abcam in a dilution of 1:40; Anti-IL23 antibody ab115759/Abcam in a dilution of 1:50;

Anti-GLI1 (H-300) sc-20687 Santa Cruz Biotechnology, Inc. in a dilution of 1:30. The tumor center of the stained slides was captured with a 20x objective on a Eclipse 80i microscope with Digital sight DS-Fi1 digital camera and NIS-Elements D Version 3.21.04 software, Nikon, Japan with same correction for brightness and white balance for all images. Based on the images, staining intensity in the tumor cells was visually semiquantified and classified by low, moderate and high expression.

Statistical analysis

The endpoint of the study was time to recurrence (TTR). TTR was calculated from the date of diagnosis of colon cancer to the date of the first observation of tumor recurrence. TTR was censored at the time of death or at the last follow-up if the patient remained tumor recurrence free at that time. The statistical power to detect or exclude effects for the SNPs we investigated depended on minor allele frequency (MAF) and SNP effect size. For the variant with the lowest MAF, SFRP rs7775, the present study had a power of 0.98, 0.89 or 0.70 to detect or exclude a HR of 2.0, 1.7 or 1.5 for recurrence. The statistical power increased with higher MAF and/ or higher HRs. The secondary end point was overall survival (OS). OS was defined as the time from date of diagnosis of colon cancer to death from any cause. Allelic distribution of the polymorphisms was tested for deviation from Hardy-Weinberg equilibrium using HW Diagnostics-Version 1.beta (Fox Chase Cancer Center, Philadelphia, PA). The distribution of polymorphisms across baseline demographic, clinical and pathological characteristics was examined using Fisher's exact test. The association of clinicopathological features and polymorphisms with TTR and OS was analyzed using Kaplan-Meier curves and log-rank test. In the multivariate Cox-regression analyses, the models were adjusted for significant clinicopathological features from univariate analysis of TTR and OS.

The true mode of inheritance of all polymorphisms tested has not been established yet and we evaluated a codominant, dominant or recessive genetic model where appropriate. The significance threshold for an overall type I error rate of 0.05 was set at $p < 0.003$ based on a conservative Bonferroni correction for multiple comparison. The interactions between polymorphisms and adjuvant chemotherapy on TTR were tested by comparing likelihood ratio statistics between the baseline and nested Cox proportional hazards models that include the multiplicative product term. Case-wise deletion for missing polymorphisms was used in univariate and multivariate analyses. The association between the GLI1 rs2228226 genotypes and GLI1, IL17 and IL21 expression in tumor was examined using chi-square test. All analyses have been performed using the SPSS 21.0 statistical software package (SPSS Inc., Sunnyvale, USA).

Results

The baseline characteristics of the 742 patients included in this analysis are summarized in Table 2. 231 patients received infusional 5-FU monotherapy, 110 patients capecitabine monotherapy, 108 patients FOLFOX, 16 patients XELOX and the treatment regimen of 18 patients was unknown. The median age at time of diagnosis was 64 years (range 27-95 years), with a median follow-up time of 64.8 months (range 1-199 months). The median TTR was 54.5 months (range 1-199 months) and the median OS was 64.8 months (range 1-199 months). The genotyping quality control provided a genotype concordance of 100%. Genotyping was successful in at least 91% of patients for each polymorphism analyzed, with the exception of DKK3 rs7396187 (86.8%). In failed cases, genotyping was not successful because of limited quantity and/ or quality of extracted genomic DNA. The genotype frequencies for all polymorphisms were within the probability limits of Hardy-Weinberg equilibrium.

In our study cohort, we found a significant association between tumor size, lymph node involvement, lymphovascular-, vascular- and perineural-invasion and clinical stage with TTR and OS. Additionally, tumor location and histopathological grade were significantly associated with OS (Table 2). When the polymorphisms were correlated with the clinicopathological features, we found a significant association between APC rs454886 G>A and tumor size ($p=0.001$) and vascular invasion ($p=0.001$), observing larger tumors and increased vascular invasion in patients carrying the wildtype. Furthermore, colon cancer patients with NOTCH2 rs11249433 T>C wildtype showed significantly increased lymphovascular invasion ($p=0.001$). No association was found between the other tested polymorphisms and clinicopathological features (data not shown).

The associations between all polymorphisms tested and TTR and OS are provided in Table 3. GLI1 rs2228226 G>C, AXIN2 rs3923086 T>G and AXIN2 rs4791171 A>G showed an association with TTR in a codominant model ($p<0.05$; Table 3). In multiple testing, only GLI1 rs2228226 G>C using a recessive genetic model remained significant for TTR in univariate analysis (HR 2.35, CI95% 1.48-3.74, $p<0.001$). Patients harbouring the homozygous mutant variant (C/C) had a median TTR of 52.2 months, in contrast to patients carrying the G/G or G/C genotype with a median TTR of 121.8 months (Figure 1). In OS analyses, no statistically significant association between the polymorphisms and OS could be found (Table 3). In the multivariate analysis including clinical stage (since clinical stage derives from tumor size and lymph node involvement, which all have been significant in univariate analysis, only clinical stage was incorporated in the multivariate model), lymphovascular-, vascular and perineural-invasion, the homozygous mutant variant of GLI1 rs2228226 G>C remained significantly associated with decreased TTR (HR 2.43, CI95% 1.52-3.87, $p<0.001$).

In interaction analysis, there was a significant association between GLI1 rs2228226 G>C and adjuvant chemotherapy with TTR ($p<0.05$). When only patients with surgery alone were analyzed, we found a highly significant association between GLI1 rs2228226 G>C and TTR (HR 3.21, CI95% 1.59-6.49, $p<0.001$). Patients harbouring the homozygous mutant variant showed a median TTR of 49.9 months, while patients harbouring the G/G or G/C genotype had a median TTR of 123.6 months (Figure 2). In multivariate analysis including clinical stage, lymphovascular-, vascular- and perineural-invasion, we observed a statistical trend towards decreased TTR in patients carrying the homozygous mutant variant (HR 2.35; CI95% 1.13-4.850; $p=0.022$). In patients with adjuvant chemotherapy, we found no significant

association between GLI1 rs2228226 G>C and TTR (HR 1.99; CI95% 1.06-3.72; p=0.031). In this subgroup, patients harbouring the C/C genotype had a median TTR of 52.5 months, in contrast to patients carrying the G/G or G/C genotype with a median TTR of 119.1 months (Figure 3).

To evaluate if “high-risk” patients based on the GLI rs2228226 G>C polymorphism (40 patients) benefit from adjuvant chemotherapy compared to surgery alone we performed a Kaplan-Meier analysis and log-rank test for this subgroup. According to the treatment regimen (surgery alone (19 patients) versus surgery plus adjuvant chemotherapy (21 patients; 8 patients received 5-FU monotherapy, 7 patient capecitabine and 6 patients FOLFOX), no significant difference in TTR was identified in this high-risk subgroup (HR 0.82; CI95% 0.35-1.95; p=0.657; Figure 4).

When we correlated the GLI1 rs2228226 genotypes using the recessive genetic model with GLI1, IL17 and IL21 expression in tumor in a subset of patients (n=27 for wildtype and heterozygous mutant and n=12 for homozygous mutant) we found no significant association (p=0.697, p=0.338, p=0.596, respectively).

Discussion

It is becoming increasingly apparent that disease progression and chemoresistance are driven by a multitude of signaling networks and the analysis of a single marker may fail to predict clinical outcome and treatment efficacy with a high degree of accuracy and reproducibility. Therefore, it is critical to adopt and implement a pathway-based approach. In the present study, we investigated germline polymorphisms in a comprehensive panel of Wnt, Notch and Hedgehog pathway genes to predict tumor recurrence in patients with stage II and III colon carcinoma. Our results indicate that GLI1 rs2228226 G>C may be an independent prognostic marker. Our findings further suggest that patients harbouring the homozygous mutant variant do not benefit from adjuvant 5-FU-based chemotherapy.

The exact molecular mechanisms involved in how the GLI1 rs2228226 G>C polymorphism exerts effect on colon carcinoma outcome are not clarified yet. Non-synonymous polymorphisms result in amino acid changes and thus may affect the protein function (40). We used the F-SNP database to predict the functional effects of the analyzed polymorphisms. F-SNP gathers computationally predicted functional information about polymorphisms, particularly aiming to facilitate identification of disease-related polymorphisms in association studies (38, 39). When used for GLI1 rs2228226 G>C, F-SNP predicted changes in splicing regulation and post-translation, thus supporting the effects seen in our study. In a recent study, however, Paez et al investigated the association of GLI1 rs2228226 with TTR in 234 patients with stage III and high-risk stage II patients, all treated with adjuvant 5-FU-based chemotherapy, but found no clinical effect (41). Moreover, in genome-wide association studies GLI1 rs2228226 has not been identified as a prognostic or predictive marker in colorectal cancer (42-44).

The Hedgehog signaling pathway induces expression of the gene *SNAIL1*, a transcription repressor of E-cadherin. Its transcriptional up-regulation is directly mediated by the transcription factor *GLI1* (17). Patched 1 (*PTCH1*), a membrane protein, functions as a tumor suppressor and normally inhibits the membrane protein *Smoothed* (*SMO*) from activating *GLI1*. The binding of one of the three Hedgehog ligands (*Sonic*, *Indian* or *Desert*) to *PTCH1* abrogates its repressive effects on *SMO* allowing the translocation of *GLI1* to the nucleus where it induces the expression of multiple target genes (45, 46). The Hedgehog signal transduction pathway regulates many processes of development and tissue homeostasis and is dysregulated in malignancies and inflammatory diseases of the gastrointestinal tract (47-50).

Increasing evidence supports the involvement of inflammation in cancer progression and metastasis (51, 52). Hedgehog signaling plays a crucial role in the inflammatory response since *Sonic Hedgehog* is critical for T lymphocyte development, adult human CD4+ T cell activation and myeloid cell maturation (53-56). Recently, Lees et al demonstrated an overall down-regulation of Hedgehog signalling pathway activity, including *GLI1* and *PTCH*, in colonic inflammation in humans. Furthermore, they identified the *GLI* rs2228226 G>C polymorphism as functionally deficient in activating *GLI*-responsive transcription in vitro, showing a 50% less efficient transcriptional activity compared to the wildtype (57). *GLI1* rs2228226 G>C encodes a change from glutamine to glutamic acid, causing a significant charge change in a conserved region adjacent to the known transactivation region of *GLI1*, that may directly modify transactivation activity and/ or affect protein stabilization (58). In addition, Lees et al showed in an established mouse model of colitis that animals carrying the mutant allele of

GLI1 rs2228226 G>C develop severe intestinal inflammation, indicating that tolerance to inflammatory stimuli requires a fully functional Hedgehog signal transduction network (51). The most highly expressed cytokine in mice harbouring the mutant allele of GLI1 rs2228226 G>C in their study was IL-23, a molecule that promotes the differentiation of T-helper IL-17-producing (TH17) cells that are involved in inflammation processes, including inflammatory bowel disease (57). IL-23 is also known as a pro-carcinogenic cytokine, which is mainly produced by tumor-associated macrophages in the tumor microenvironment, via direct transcriptional activation of the IL-23/p19 gene (59). In the study by Lees et al, also IL-17, a cytokine closely associated with IL-23, was markedly up-regulated in animals harbouring the GLI1 rs2228226 G>C mutant variant (57). Grivennikov et al investigated mechanisms responsible for tumor-elicited inflammation in a mouse model of colorectal carcinogenesis, which, like human colorectal carcinoma, also exhibited up-regulation of IL-23 and IL-17 (59). They found that IL-23 signaling promotes tumor growth and progression, and the development of tumoral IL-17 response, resulting in an additional aggravation of disease progression (60). Efforts to target pathogenic Hedgehog signaling have steadily progressed from the laboratory to the clinic, and the recent approval of vismodegib for patients with advanced basal cell carcinoma represents an important milestone (61-66). However, in a recent phase II study, vismodegib did not add to the efficacy of standard first-line treatment for metastatic colorectal cancer (67).

In our study cohort, we found a statistically significant association between GLI1 rs2228226 G>C and TTR, showing a decreased TTR in patients carrying the homozygous mutant genotype. Hence, we hypothesize that colon carcinoma patients harbouring the functionally deficient homozygous mutant variant, which is associated with up-regulation of IL-23 and IL-

17 are more likely to develop a recurrent disease, due to a supportive inflammatory microenvironment for tumor growth. However, we could not experimentally underline this biological function since the GLI1 rs2228226 genotypes were not significantly associated with GLI1, IL17 and IL21 expression in tumor in a subset of our patient cohort. Our results further suggest that patients harbouring the homozygous mutant variant of GLI1 rs2228226 G>C do not benefit from adjuvant 5-FU-based chemotherapy. We also found a significant association between APC rs454886 G/G and larger tumor size and increased vascular invasion, furthermore, patients with NOTCH2 rs11249433 TT showed an increased lymphovascular invasion. F-SNP predicted changes in the transcriptional regulation for the intronic APC rs454886 G>A. No prediction could be provided for the intergenic located NOTCH2 rs11249433 T>C by the software (38, 39). Since the biological function of these SNPs is unknown, these associations remain to be elucidated.

The strength of the present study is the large sample size and the long follow-up period. However, because of the retrospective study design a selection bias cannot be fully excluded. The subgroup of “high-risk” GLI1 rs2228226 C/C included overall only 40 patients and only 21 patients treated with various chemotherapy regimens. Therefore, it is currently unknown if this association is truly significant and/ or if only patients with monotherapy or both, mono- and combination therapy do not benefit in this “high-risk” subgroup. Another limitation is the lack of the MSI-status in our study cohort, hence the evaluation of GLI1 rs2228226 G>C in comparison to MSI was not feasible. Finally, the method of preservation of the tissue samples was performed by 3 different institutions over a number of years, undermining the consistency of sample preparation.

In conclusion, this study provides the first evidence that GLI1 rs2228226 G>C may predict early tumor recurrence in stage II and III colon carcinoma patients. Prospective studies are warranted to validate our findings.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012;62:10-29.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 2010;46:765-81.
3. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. *Br J Surg* 2006;93:1115-22.
4. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. *Semin Oncol* 2011;38:552-60.
5. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. *Oncologist* 2010;15:390-404.
6. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. *Cancer Treat Rev* 2010;36:550-6.
7. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. *Curr Opin Oncol* 2009;21:369-73.
8. LaBarge MA. The difficulty of targeting cancer stem cell niches. *Clin Cancer Res* 2010;16:3121-9.
9. Clevers H. The cancer stem cell: premises, promises and challenges. *Nat Med* 2011;17:313-9.
10. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. *Clin Cancer Res* 2010;16:3113-20.
11. Kiesslich T, Berr F, Alinger B, Kemmerling R, Pichler M, Ocker M, et al. Current status of therapeutic targeting of developmental signalling pathways in oncology. *Curr Pharm Biotechnol* 2012;13:2184-220.
12. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? *Clin Cancer Res* 2010;16(12):3153-62.
13. Polakis P. Wnt signaling and cancer. *Genes Dev* 2000;14:1837-51.
14. Saif MW, Chu E. Biology of colorectal cancer. *Cancer J* 2010;16:196-201.

15. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. *Clin Cancer Res* 2010;16:3141-52.
16. Miele L, Golde T, Osborne B. Notch signaling in cancer. *Curr Mol Med* 2006;6:905-18.
17. Merchant AA, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. *Clin Cancer Res* 2010;16:3130-40.
18. Monzo M, Moreno I, Artells R, Ibeas R, Navarro A, Moreno J, et al. Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. *Cancer Lett* 2006;233:117-23.
19. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. *J Clin Oncol* 2010;28:4029-37.
20. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, Kawakami K, et al. Wnt antagonist gene polymorphisms and renal cancer. *Cancer* 2009;115:4488-503.
21. Shanmugam KS, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B. The functional genetic variant Arg324Gly of frizzled-related protein is associated with colorectal cancer risk. *Carcinogenesis* 2007;28:1914-7.
22. Berndt SI, Huang WY, Yeager M, Weissfeld JL, Chanock SJ, Hayes RB. Genetic variants in frizzled-related protein (FRZB) and the risk of colorectal neoplasia. *Cancer Causes Control* 2009;20:487-90.
23. Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W, et al. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008;17:2101-8.
24. Kanzaki H, Ouchida M, Hanafusa H, Yano M, Suzuki H, Aoe M, et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. *Int J Mol Med* 2006;18:279-84.
25. Hazra A, Fuchs CS, Chan AT, Giovannucci EL, Hunter DJ. Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. *Cancer Causes Control* 2008;19:975-80.
26. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J, Brenner H. Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer. *Carcinogenesis* 2010;31:1381-6.

27. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. *Nat Genet* 2009;41:885-90.
28. Slattery ML, Folsom AR, Wolff R, Herrick J, Caan BJ, Potter JD. Transcription factor 7-like 2 polymorphism and colon cancer. *Cancer Epidemiol Biomarkers Prev* 2008;17:978-82.
29. Fu YP, Edvardsen H, Kaushiva A, Arhancet JP, Howe TM, Kohaar I, et al. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. *Mol Cancer* 2010;9:113.
30. Wang YC, Xue HP, Wang ZH, Fang JY. An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. *Mol Biol Rep* 2013;40:4637-44.
31. Mirakhorli M, Rahman SA, Abdullah S, Vakili M, Rozafzon R, Khoshzaban A. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. *Mol Med Rep* 2013;7:613-7.
32. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, et al. Identification of novel germline polymorphisms governing capecitabine sensitivity. *Cancer* 2012;118:4063-73.
33. Zhang X, Sun B, Lu Z. Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-Fluorouracil toxicity in 60 colorectal cancer patients in China. *Int J Med Sci* 2013;10:894-902.
34. Lv H, Li Q, Qiu W, Xiang J, Wei H, Liang H, Sui A, Liang J. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. *Cancer Invest* 2013;31:24-8.
35. Cortejoso L, López-Fernández LA. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. *Pharmacogenomics* 2012;13:1173-91.
36. Alonzo TA. Standards for reporting prognostic tumor marker studies. *J Clin Oncol* 2005;23:9053-4.
37. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies. *J Clin Oncol* 2005;23:9067-72.

38. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. *Nucleic Acids Res* 2008;36:D820-4.
39. Lee PH, Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. *Bioinformatics* 2009;25:1048-55.
40. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. *Annu Rev Genomics Hum Genet* 2006;7:61-80.
41. Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhaim L, et al. Association of common gene variants in the WNT/ β -catenin pathway with colon cancer recurrence. *Pharmacogenomics J* 2013, in press.
42. Wong SH, Sung JJ, Chan FK, ToKF, Ng SS, Wang XJ, et al. Genome-wide association and sequencing studies on colorectal cancer. *Semin Cancer Biol* 2013;23:502-11.
43. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, et al. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. *Carcinogenesis* 2012;33:1327-31.
44. Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guino E, Duran G, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. *Pharmacogenomics J* 2013;13:209-17.
45. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. *Nature* 2001;411:349-54.
46. Wang Y, McMahon AP, Allen BL. Shifting paradigms in Hedgehog signaling. *Curr Opin Cell Biol* 2007;19:159-65.
47. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev* 2001;15:3059-87.
48. Lees C, Howie S, Sartor RB, Satsangi J. The hedgehog signalling pathway in the gastrointestinal tract: implications for development, homeostasis, and disease. *Gastroenterology* 2005;129:1696-710.
49. Madison BB, Braunstein K, Kuizon E, Portman K, Qiao XT, Gumucio DL. Epithelial hedgehog signals pattern the intestinal crypt-villus axis. *Development* 2005;132:279-89.
50. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signalling in cancer. *Nature* 2008;455:406-10.

51. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;420:860-7.
52. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008;454:436-44.
53. El Andaloussi A, Graves S, Meng F, Mandal M, Mashayekhi M, Aifantis I. Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus. *Nat Immunol* 2006;7:418-26.
54. Lowrey JA, Stewart GA, Lindey S, Hoyne GF, Dallman MJ, Howie SE, et al. Sonic hedgehog promotes cell cycle progression in activated peripheral CD4(+) T lymphocytes. *J Immunol* 2002;169:1869-75.
55. Stewart GA, Lowrey JA, Wakelin SJ, Fitch PM, Lindey S, Dallman MJ, et al. Sonic hedgehog signaling modulates activation of and cytokine production by human peripheral CD4+ T cells. *J Immunol* 2002;169:5451-7.
56. Varas A, Hernández-López C, Valencia J, Mattavelli S, Martínez VG, Hidalgo L, et al. Survival and function of human thymic dendritic cells are dependent on autocrine Hedgehog signaling. *J Leukoc Biol* 2008;83:1476-83.
57. Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, et al. Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. *PLoS Med* 2008;5:e239.
58. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual degradation signals control Gli protein stability and tumor formation. *Genes Dev* 2006;20:276-81.
59. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. *Cancer Cell* 2009;15:114-23.
60. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. *Nature* 2012;491:254-8.
61. Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. *Clin Cancer Res* 2013;19:2289-93.
62. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med* 2012;366:2180-8.

63. Queiroz KC, Spek CA, Peppelenbosch MP. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. *Drug Resist Updat* 2012;15:211-22.
64. Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. *Oncologist* 2012;17:1090-9.
65. Onishi H, Katano M. Hedgehog signaling pathway as a therapeutic target in various types of cancer. *Cancer Sci* 2011;102:1756-60.
66. Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. *Cancer Sci* 2012;103:1272-9.
67. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Clin Cancer Res* 2013;19:258-67.

Figure Legends

Figure 1

Association between GLI1 rs2228226 G>C and TTR in all colon carcinoma patients

TTR, time to recurrence

Figure 2

Association between GLI1 rs2228226 G>C and TTR in colon carcinoma patients with surgery alone

TTR, time to recurrence

Figure 3

Association between GLI1 rs2228226 G>C and TTR in colon carcinoma patients with adjuvant chemotherapy

TTR, time to recurrence

Figure 4

Association in colon carcinoma patients homozygous mutant (C/C) for GLI1 rs2228226 G>C (40 patients) between adjuvant chemotherapy (21 patients) or surgery alone (19 patients) and TTR

TTR, time to recurrence

Table 1

Analyzed Wnt/ Notch/ Hedgehog pathway genes and polymorphisms

Pathway	Gene	Function	rs-number	Base exchange	Location	Association
WNT	SFRP	Soluble Wnt receptor	rs1802073	C>A	Non-synonymous	Rectal cancer risk (26)
WNT	SFRP	Soluble Wnt receptor	rs288326	G>A	Non-synonymous	CRC risk (21, 22)
WNT	SFRP	Soluble Wnt receptor	rs7775	C>G	Non-synonymous	CRC risk (21, 22)
WNT	DKK2	Inhibits Wnt by binding to LRP5/6	rs17037102	G>A	Non-synonymous	RCC outcome (20)
WNT	DKK3	Inhibits Wnt by binding to LRP5/6	rs3206824	A>G	Non-synonymous	RCC risk (20)
WNT	DKK3	Inhibits Wnt by binding to LRP5/6	rs1472189	C>T	3 UTR	RCC outcome (20)
WNT	DKK3	Inhibits Wnt by binding to LRP5/6	rs7396187	C>G	Intron	RCC risk (20)
WNT	AXIN2	Suppressor	rs11079571	A>G	Intron	BC risk (23)
WNT	AXIN2	Suppressor	rs4791171	A>G	Intron	BC risk (23)
WNT	AXIN2	Suppressor	rs3923086	T>G	Intron	BC risk (23)
WNT	AXIN2	Suppressor	rs3923087	A>G	Intron	BC risk (23)
WNT	APC	Suppressor	rs454886	T>C	Intron	BC risk (23)
WNT	AXIN2	Suppressor	rs2240308	G>A	Non-synonymous	NSCLC risk (24)
WNT	MYC	Wnt enhancer	rs6983267	G>T	8q24, non-coding, near MYC	CRC risk (27)
WNT	TCF7L2	Transcription factor activator	rs12255372	G>T	Intron	CRC risk (25)
WNT	TCF7L2	Transcription factor	rs7903146	C>T	Intron	CRC risk (28)

		activator				
NOTCH	NOTCH2	NOTCH receptor	rs11249433	T>C	1p11.2, within non-coding gene	BC (29)
HEDGEHOG	GLI1	transcriptional activator	rs2228226	G>C	Non-synonymous	IBD risk (47)

CRC, colorectal cancer; RCC, renal cell cancer; BC, breast cancer; NSCLC, non small cell lung cancer; IBD, inflammatory bowel disease; NA, not available

Table 2

Clinicopathological characteristics and TTR and OS in univariate analysis

Parameter	N	%	TTR		OS	
			HR (95%CI)	p-value	HR (95%CI)	p-value
Gender						
Male	416	56.1	1 (reference)	0.750	1 (reference)	0.401
Female	326	43.9	0.96 (0.74-1.24)		0.89 (0.67-1.17)	
Tumor location						
Left	274	36.9	1 (reference)	0.168	1 (reference)	0.025
Right	468	63.1	0.83 (0.64-1.08)		0.73 (0.55-0.96)	
Tumor size						
T1	12	1.6	1 (reference)	<0.001	1 (reference)	<0.001
T2	32	4.3	0.97 (0.10-9.35)		1.33 (0.16-11.43)	
T3	536	72.2	3.27 (0.46-23.36)		2.26 (0.32-16.15)	
T4	162	21.8	6.58 (0.91-47.35)		5.56 (0.77-40.05)	
Lymph node involvement						
N0	298	40.2	1 (reference)	<0.001	1 (reference)	<0.001
N1	276	37.2	1.44 (1.03-2.02)		1.33 (0.93-1.88)	
N2	167	22.5	3.86 (2.80-5.32)		3.12 (2.23-4.36)	
Unknown	1	0.1				
Tumor grade						
G1	37	5	1 (reference)	0.337	1 (reference)	0.032
G2	480	64.7	1.16 (0.57-2.37)		0.77 (0.37-1.57)	
G3	224	30.2	1.40 (0.68-2.91)		1.12 (0.54-2.33)	
Unknown	1	0.1				
Lymphovascular invasion						
No	532	71.7	1 (reference)	0.001	1 (reference)	0.009
Yes	210	28.3	1.58 (1.21-2.06)		1.47 (1.10-1.96)	
Vascular invasion						
No	665	89.6	1 (reference)	<0.001	1 (reference)	0.001
Yes	77	10.4	2.40 (1.73-3.32)		2.06 (1.43-2.96)	
Perineural invasion						
No	721	97.2	1 (reference)	<0.001	1 (reference)	0.006
Yes	21	2.8	3.64 (2.12-6.26)		2.45 (1.29-4.62)	
Clinical stage						
II	295	39.8	1 (reference)	<0.001	1 (reference)	<0.001
III	446	60.1	2.26 (1.69-3.03)		1.92 (1.42-2.58)	
Unknown	1	0.1				
Adjuvant chemotherapy						
No	256	34.5	1 (reference)	0.239	1 (reference)	0.300
Yes	483	65.1	1.18 (0.90-1.56)		0.86 (0.65-1.14)	
Unknown	3	0.4				

TTR, time to recurrence; OS, overall survival

Table 3

Association between the polymorphisms and TTR and OS in univariate analysis

Polymorphism	N	TTR		OS	
		HR (95%CI)	p-value	HR (95%CI)	p-value
SFRP rs1802073					
C/C	217	0.98 (0.78-1.23)	0.858	0.93 (0.72-1.19)	0.568
C/A	231				
A/A	63				
SFRP rs288326					
G/G	7	1.04 (0.74-1.48)	0.809	0.78 (0.55-1.10)	0.156
G/A	103				
A/A	363				
SFRP rs7775					
C/C	6	1.01 (0.66-1.54)	0.967	1.04 (0.65-1.68)	0.866
C/G	64				
G/G	436				
DKK2 rs17037102					
G/G	408	0.83 (0.56-1.23)	0.351	0.89 (0.58-1.37)	0.586
G/A	88				
A/A	4				
DKK2 rs3206824					
A/A	288	1.01 (0.79-1.30)	0.922	1.05 (0.80-1.37)	0.745
A/G	188				
G/G	34				
DKK2 rs1472189					
C/C	241	0.90 (0.71-1.15)	0.405	1.11 (0.85-1.44)	0.438
C/T	220				
T/T	50				
DKK2 rs7396187					
C/C	14	1.19 (0.87-1.63)	0.285	0.91 (0.66-1.26)	0.575
C/G	156				
G/G	283				
AXIN2 rs11079571					
A/A	22	1.23 (0.92-1.64)	0.171	1.08 (0.79-1.48)	0.645
A/G	189				
G/G	283				
AXIN2 rs4791171					
A/A	205	0.72 (0.56-0.93)	0.012	0.80 (0.60-1.05)	0.108
A/G	251				
G/G	52				
AXIN2 rs3923086					
T/T	107	1.31 (1.05-1.65)	0.019	1.19 (0.93-1.52)	0.160
T/G	261				
G/G	142				
AXIN2 rs3923087					
A/A	255	0.78 (0.60-1.02)	0.073	0.85 (0.63-1.14)	0.270
A/G	210				
G/G	32				
APC rs454886					

T/T	267				
T/C	201	0.76 (0.60-1.01)	0.054	0.79 (0.58-1.07)	0.121
C/C	30				
AXIN2 rs2240308					
G/G	114				
G/A	267	0.80 (0.64-1.00)	0.054	0.90 (0.71-1.15)	0.407
A/A	129				
Near MYC rs6983267					
G/G	112				
G/T	252	0.85 (0.66-1.08)	0.189	0.95 (0.73-1.24)	0.719
T/T	112				
TCF7L2 rs12255372					
G/G	252				
G/T	199	1.09 (0.85-1.40)	0.485	0.10 (0.76-1.31)	0.974
T/T	40				
TCF7L2 rs7903146					
C/C	248				
C/T	205	1.06 (0.83-1.36)	0.649	0.93 (0.71-1.22)	0.601
T/T	43				
NOTCH2 rs11249433					
T/T	176				
T/C	244	0.96 (0.77-1.19)	0.682	1.05 (0.83-1.33)	0.696
C/C	85				
GLI1 rs2228226					
G/G	249				
G/C	209	1.36 (1.06-1.74)	0.015	1.22 (0.93-1.61)	0.156
C/C	40				

TTR, time to recurrence; OS, overall survival

Figure 1




Figure 2




Figure 3





Figure 4



Clinical Cancer Research

A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients

Joanna Szkandera, Martin Pichler, Gudrun Absenger, et al.

Clin Cancer Res Published OnlineFirst January 27, 2014.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-13-1517
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.